sermorelin protocol: Frequently asked questions

Resume your normal dose on the next scheduled night. Do not double-dose to compensate. Missing 2–3 injections within a 16-week protocol doesn't significantly alter cumulative IGF-1 response if the remaining doses maintain consistency. GH pulse patterns re-establish within 24–36 hours of resuming injections. Patients who miss more than 4 injections within any 14-day period should extend their protocol by one week to maintain the target number of total administered doses.

BPC-157 has a half-life of approximately 4 hours, meaning daily dosing maintains consistent tissue-level concentration. Missing 2–3 days resets local VEGF upregulation but doesn't reverse prior gains. Resume at your standard dose without compensatory doubling. Sermorelin has a similar short half-life but works through pulsatile GH release, so missing doses reduces cumulative IGF-1 elevation. If you miss more than 5 consecutive sermorelin doses, expect a 10–15% drop in IGF-1 levels that takes 7–10 days to recover once dosing resumes.

Verify peptide storage and reconstitution first. Temperature excursions or contaminated bacteriostatic water are the most common causes of ineffective peptides. If storage was correct, consider increasing BPC-157 to 500mcg daily or adding a second daily dose (250mcg morning, 250mcg evening). For sermorelin, bloodwork confirming IGF-1 elevation is the gold standard. If IGF-1 hasn't increased by at least 20–30% from baseline, you may be a non-responder or dosing too low. Some individuals require 300–400mcg sermorelin nightly to achieve therapeutic IGF-1 levels.

Administer both peptides as planned. Delayed initiation doesn't eliminate efficacy, it just means you're working through chronic inflammation rather than acute healing. BPC-157 still promotes angiogenesis in fibrotic tissue, and sermorelin still elevates systemic IGF-1. Expect 6–8 weeks instead of 4–6 weeks to see measurable improvement, and consider extending sermorelin dosing to 10–12 weeks if tissue remodelling hasn't plateaued by week 8.

Stop both peptides immediately and consult your prescribing physician. Worsening pain, swelling, or loss of function during peptide therapy usually indicates improper diagnosis (e.g., treating a partial tear that's actually a complete rupture) or biomechanical overload (returning to activity too soon). Peptides accelerate healing. They don't replace rest, load management, or appropriate medical imaging. In our experience, this scenario is almost always user error (overtraining during recovery) rather than peptide-related adverse effects.